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chemosensitive relapses after chemotherapy and autologous
HSCT. Source of HSCT included HLA-matched siblings (n 
41), matched unrelated donors (n  6) and parents (n  1).
Forty-ﬁve patients received myeloablative and 3 received reduced
intensity conditioning. The median EFS and OS were 38 and 40
months and at 160 months, the EFS and OS were 47% and 50%.
When patients with diffuse large B-cell lymphoma were separately
analyzed, the EFS and OS at 40 months were about 52% and none
of the patients had disease relapse or mortality thereafter. Con-
clusion: We demonstrated that allogeneic HSCT may offer a cure
for high risk NHL patients. Our results compared favorably with
those reported in the literature.
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RECIPIENT OUTCOMES DATA COLLECTION AND REPORTING FOR
CORD BLOOD BANK FOLLOW-UP AND QUALITY ASSURANCE PUR-
POSES: THE NATIONAL MARROW DONOR PROGRAM EXPERIENCE
Halet, M.1, Confer, D.1, Welte, K.1, Matlack, M.1, King, R.1, Boo, M.1,
Kurtzberg, J.2 1. National Marrow Donor Program, Minneapolis, MN;
2. Duke University Medical Center, Durham, NC.
Cord blood banks (CBB) are required to monitor clinical out-
comes of cord blood unit (CBU) transplants performed by trans-
plant centers (TC). Obtaining accurate and timely follow-up data
on clinical outcomes from the TC can be very difﬁcult. The
National Marrow Donor Program (NMDP), by virtue of their
comprehensive activities with member network centers, collects
outcomes data on recipients transplanted with either cord blood or
adult donor cells. NMDP member transplant centers are required
to submit data at deﬁned intervals as part of their participation
agreement. A system is in place to monitor compliance that in-
cludes a due process procedure for non-compliant centers. Recip-
ients sign an IRB-approved consent form for data submission to
the NMDP. All submitted data are veriﬁed through system checks
at time of data entry. Identiﬁed errors are subject to a formal error
correction process. Transplant centers are audited on a four year
cycle to assure the accuracy and integrity of the data provided. At
any given time,	90% of NMDP centers are compliant with forms
submission requirements. The data elements include information
on the results of the thaw, infusion related reactions, preparative
regimens, neutrophil and platelet engraftment, GVHD, relapse,
survival and death. Member cord blood banks receive a quarterly
report from the NMDP which includes comprehensive data on the
individual recipients for which their CBUs were used. The data
include recipient demographics, infused cell dose, degree of HLA
match, engraftment, GVHD, relapse, survival, and cause of death.
While outcomes data are reported quarterly to member banks,
thaw data are reported and reviewed on a continuous basis. TNC
recoveries that are low (60%) or high (	100%) are reviewed by
NMDP staff to detect problems with CBU potency that might be
linked to a certain bank, shipping procedure or thawing protocol at
a TC. Future directions include trending analysis reports and
review with the NMDP Quality Standards subcommittee. The
NMDP’s process for reporting quality assurance data to member
banks is a valuable service that is unlikely to be feasible in a single
bank.
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ISOPHOSPHORAMIDE MUSTARD-LYSINE (IPM-L; ZIO-201): A NEW AL-
KYLATOR FOR BONE MARROW TRANSPLANTS
Morgan, L.1, Struck, R.2, Rodgers, A.3, Jursic, B.4, Waud, W.3,
Papagiannis, C.5, Gale, R.P.6 1. DEKK-TEC, Inc., New Orleans, LA;
2. Cancer Medica, LLC, Birmingham, AL; 3. Southern Research Insti-
tute, Birmingham, AL; 4. Chemistry Department, University of New
Orleans, LA; 5. MPI Research, Mattawan, MI; 6. ZIOPHARM On-
cology, Charlestown, MA.
Alkylators are widely used in conditioning regimens for bone
marrow transplants. IPM is a bi-functional alkylator with cross-
linking through G:C base sequences resulting in irreparable inter-
strand DNA cross-linking producing cell death. IPM alkylates
DNA as a phosphorodiamidate and may cross-link DNA differ-
ently from phosphoramide mustard (PM) the major DNA-cross-
linking moiety of cyclophosphamide (CPA). IPM is active in di-
verse cancer models but its chemical instability precluded
pharmaceutical development; CPA and ifosfamide (IFOS) were
developed as alternatives. We stabilized IPM with lysine (IPM-L;
ZIO-201) and tested it in preclinical sub-acute pharmacology and
toxicology models and in mice with human cancer xenografts.
ZIO-201 and IPM were given IV daily  3 d. ZIO-201 sub-acute
LD10/50 in adult mice was 133 and 220 mg/kg (combined sexes)
compared to 119 and 149 mg/kg for IPM. Bone marrow failure was
the dose-limiting toxicity (DLT) of both drugs. In the MX-1
human breast cancer model, ZIO-201 was better than IPM: MTD:
93 vs. 40 mg/kg/dose and tumor versus control life extension
(T-C): 10.2 versus 2.1 d. Because ZIO-201 (unlike cyclophospha-
mide [CPA] and ifosfamide [IFOS]) is not metabolized to acrolein
or acetaldehydes, there was no kidney, bladder or CNS toxicity.
ZIO-201 is in phase-1 trials in humans: data will be presented.
Using ZIO-201 may increase the safety and efﬁcacy of this class of
alkylators in clinical settings where high-dose CPA and IFOS are
used, like bone marrow transplants. Possible dose increases and
activity in CPA- and IFOS-resistant cancers may broaden the
target range. Supported by grant R44 CA83552 from the NCI/
SBIR program.
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ADOPTIVE IMMUNOTHERAPY WITH TUMOR-DERIVED DONOR LYM-
PHOCYTES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Hardy, N.M.1, Fellowes, V.1, Mariotti, J.1, Carter, C.2, June, C.3,
Levine, B.3, Hakim, F.1, Vonderheide, R.3, Gress, R.1, Read, E.J.2,
Fowler, D.1, Bishop, M.R.1 1. National Cancer Institute, National
Institutes of Health (NIH), Bethesda, MD; 2. Clinical Center, NIH,
Bethesda, MD; 3. University of Pennsylvania, Philadelphia, PA.
Treatment of refractory or recurrent malignancy with donor
lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell
transplantation (alloHSCT) is limited in efﬁcacy, and graft-vs-
tumor (GVT) is often accompanied by graft-versus-host disease
(GVHD). After alloHSCT, lymphocytes inﬁltrating residual tu-
mor are likely of donor origin. Compared with DLI, they may
provide enhanced antigen speciﬁcity and maintain tumor-speciﬁc
homing, thus generate better GVT with less GVHD. We are
testing this hypothesis through administration of ex-vivo activated
tumor-derived lymphocytes (TDL) after alloHSCT. Clinical eval-
uation of TDL therapy was initiated with a 51 year-old woman for
metastatic breast cancer whose disease progressed after matched-
sibling alloHSCT and subsequent conventional therapy plus DLI.
Metastases were surgically removed two weeks after administration
of unmanipulated DLI. Lymphocytes were liberated from 9.4 cm
of tumor and expanded for 14 days with anti-CD3/CD28-coated
magnetic beads (3:1 bead-to-total nucleated cell ratio) and media
containing IL-2 (100 or 1000 IU/mL). The cell products from the
two culture conditions were similar. The process yielded 42.5 
106 cells, 33% expressing CD3, and generated 14.7  109 TDL,
85% expressing CD3 (a 3.1-log T cell expansion). There was no
tumor contamination of the T cell product by immunohistochem-
istry. Chimerism analysis revealed the TDL to be of donor origin.
Flow cytometry showed an increase in the CD4/CD8 ratio from
1.3 to 1.9 after expansion. 76% of CD8 and 31% of CD4 cells
secrete IFN-, and none secretes IL-2, IL-4 or IL-10. 76% of
CD8 and 57% of CD4 cells expressed CXCR3. Three infusions of
TDL were given in a dose-escalating manner (5, 25 and 100  106
CD3 cells/kg). Two additional infusions were given in conjunc-
tion with low-dose IL-2, the second of which was preceded by one
cycle of paclitaxel and trastuzumab cytoreductive therapy. No
infusion-related or delayed toxicities were observed. The patient
had no evidence of GVHD, even after the highest dose of 108
allogeneic T cells. Evaluation of the remaining thoracic lesion
demonstrated progressive disease after the ﬁrst two TDL infu-
sions, transient disease stability after the third and fourth infusions,
and at present, the patient has stable disease one month after the
ﬁfth infusion. This is the ﬁrst clinical report of the application of
TDL and represents a novel approach for adoptive immunother-
apy in the setting of alloHSCT.
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